Medical News

RSS

Sangart's MP4CO receives orphan drug designation for acute pain in sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that its investigational biopharmaceutical product, MP4CO, has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA) for use in treating acute painful sickling crises in patients with sickle cell disease.

15 Nov 2010

New investigational drug is well tolerated in children with nmCF

PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine.

15 Nov 2010

State roundup: Colorado high-risk insurance pool; Ariz. and Mich. medical marijuana issues; high-deductible insurance

Nearly 500 people in Colorado have applied for the new high-risk health-insurance pool since the program started in the state 10 weeks ago. About 430 people who already have health problems that make it difficult to get private insurance have been enrolled; 43 applications are pending.

15 Nov 2010

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

15 Nov 2010

Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

Cyplasin Biomedical is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. The Company is pleased to announce that it has selected Aurobindo Pharma located in Hyderabad , India to supply the active pharmaceutical ingredient (API) component for its Ribavirin drug product called C-Virin.

15 Nov 2010

KHN column: For health overhaul, implementation is now job one

In his latest Kaiser Health News column, Timothy Jost writes, The foremost concern of many of us who fought for health care reform is what its fate will be in the post-midterm-election world.

15 Nov 2010

diaDexus third quarter revenue increases 26% to $3.2 million

diaDexus, Inc., a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced financial results for the third quarter of 2010.

15 Nov 2010

National health disparities conference wraps up with creative approaches, expectations for new healthcare reform

Focusing on the disparities in the quality of health care across demographic groups, the Fourth Annual National Conference on Health Disparities brought together White House officials and national and local healthcare executives to address a series of key questions about non-medical determinants of health quality and to recommend strategies to bring more equitable healthcare access to the underserved. The determinants discussed at the four-day-long conference, which began November 10, 2010 and concluded Saturday, November 13, 2010, included education levels, health literacy, poverty, public safety, community design, access to care, environmental quality and personal, government and corporate responsibility.

15 Nov 2010

Novel heart attack treatment results presented at premier USA cardiology forum

Regenerative medicine company Mesoblast Limited (ASX:MSB; USADR:MBLTY) has announced that positive preclinical trial results were presented at the American Heart Association’s annual conference in Chicago showing that the company’s proprietary “off-the-shelf” stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.

15 Nov 2010

Erroneous defibrillators: FDA new initiative to check safety

More problems are being reported in external defibrillators, the life-saving medical devices located in emergency rooms, airports and other public places. These Automated external defibrillators, or AEDs are generally used in patients who have suffered sudden cardiac arrest if used in the first few minutes after their collapse. They deliver electrical energy to the heart to restore its normal rhythm.

15 Nov 2010

Emerging blood thinners to prevent stroke

As blood thinners emerge in the market for stroke prevention many experts believe is still too early to predict how they will stack up in the $15 billion a year market.

15 Nov 2010

Young marijuana users suffer most cognitive damage: Study

Many marijuana smokers begin early. A new study shows that these people did much worse on tests of executive brain function than those who started smoking when they were older. Researchers highlight the danger posed by marijuana and the need to develop effective strategies to reduce marijuana use, especially among young people in their study.

15 Nov 2010

Too many Ozzie kids can’t swim: 2010 National Drowning Report

Much to the concern of the Royal Life Saving Society, more and more Australian children do not know how to swim, or lack the skills to keep themselves alive in the water. It is estimated that up to 20 per cent of children finish primary school without the ability to swim the length of an Olympic-sized swimming pool. For example more than 50,000 or a fifth of NSW students will start high school next year unable to swim 50 meters.

15 Nov 2010

WaferGen third quarter revenue increases to $633,000

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today reported financial results for the three and nine months ended September 30, 2010.

15 Nov 2010

High-dose prescription omega-3 does not reduce recurrence of atrial fibrillation

Although some data have suggested that omega-3 fatty acid supplements, such as from fish oil, may improve treatment of atrial fibrillation, a randomized trial with more than 600 patients finds that treatment with high-dose prescription omega-3 did not reduce the recurrence of atrial fibrillation over six months, according to a study that will appear in the December 1 issue of JAMA. The study is being released early online because it will be presented at the American Heart Association's annual meeting.

15 Nov 2010

MEDecision earns NCQA Healthcare Effectiveness Data and Information Set Software Certification

MEDecision, Inc., a leading provider of collaborative healthcare management solutions, has earned the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS®) Software Certification for its programs that identify "care opportunities."

15 Nov 2010

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

15 Nov 2010

Dyadic third quarter total revenue decreases to $2.0 million

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the third quarter ended September 30, 2010.

15 Nov 2010

BioTime third quarter total revenues increase 82% to $815,284

BioTime, Inc. today reported financial results for the quarter ended September 30, 2010 and provided an update on recent corporate developments.

15 Nov 2010

MedClean enters distribution agreement with SunBelt

MedClean Technologies, the leading provider of on-site technology for the treatment and disposal of medical waste and the destruction of confidential documents and related media, today announced it has signed a distribution agreement with SunBelt Medical Services, Inc. With this agreement, MedClean now has 11 regional distributors covering 41 states, one national partner targeting the Veteran's Administration, and one international partner covering Canada.

15 Nov 2010